imusyn Launches Revolutionary Ready-to-Use T Cell Staining Reagents
Novel T Cell Staining Reagents Now Available at imusyn’s Web Shop imusyn is excited to announce the release of Dyemer
Read more
T-cell
3-D Life Hydrogel Used in Novel Microfluidic Platform to Investigate CAR-T Cell Therapy for Solid Tumors
Cellendes GmbH is pleased to announce that its pioneering 3-D Life Hydrogel has been successfully utilised in a novel microfluidic
Read more
T Cell Staining Reagents
imusyn’s Dyemer & myDyemer are a pioneering class of ready-to-use and loadable T Cell staining reagents, developed for precise quantification
Read more
New 3D Cell-based Model Unveils Insights on Immune Cells in Alzheimer’s Disease
Researchers have devised a novel human 3D model for Alzheimer’s Disease, enabling the study of immune cell involvement in the
Read more
Recombinant HLA Proteins
imusyn offers an unmatched portfolio of top-tier recombinant HLA class I and class II proteins, produced as truncated, soluble antigens
Read more
Peptide Binding Analysis
imusyn’s imuPep Class I Peptide Binding Analysis is designed to determine the stability of peptide/HLA class I complexes, allowing researchers
Read more
BMS and Cellares Enter $380m CAR T Cell Therapy Capacity & Supply Deal
Bristol Myers Squibb (BMS) announced on Monday it has entered a worldwide capacity reservation and supply agreement with the California-headquartered Integrated
Read more
Nutcracker’s mRNA Drug Candidate for Prostate Cancer Effectively Targets CD3 T cells
Preclinical data shows that Nutcracker’s mRNA drug candidate NTX-470 effectively targets CD3 T cells, demonstrating selective engagement with minimal unintended
Read more
FDA Approves J&J and Bristol Myers Cell Therapies for Refractory Multiple Myeloma
The U.S. Food and Drug Administration has approved the use of cell therapies developed by Johnson & Johnson (JNJ.N) and Bristol Myers Squibb (BMY.N) for treating
Read more
FDA Greenlights Iovance’s AMTAGVI™ as First T-cell Therapy for Solid Tumor Cancer
Iovance Biotherapeutics, Inc., a leading biotechnology firm specialising in pioneering, developing, and delivering advanced polyclonal tumor infiltrating lymphocyte (TIL) cell
Read more